These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047 [TBL] [Abstract][Full Text] [Related]
3. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894 [TBL] [Abstract][Full Text] [Related]
4. Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models. Ye J; Chen L; Waltermire J; Zhao J; Ren J; Guo Z; Bartlett DL; Liu Z Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473379 [TBL] [Abstract][Full Text] [Related]
5. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553 [TBL] [Abstract][Full Text] [Related]
6. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Moon EK; Wang LS; Bekdache K; Lynn RC; Lo A; Thorne SH; Albelda SM Oncoimmunology; 2018; 7(3):e1395997. PubMed ID: 29399394 [TBL] [Abstract][Full Text] [Related]
7. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352 [TBL] [Abstract][Full Text] [Related]
9. Arming oncolytic viruses to leverage antitumor immunity. de Gruijl TD; Janssen AB; van Beusechem VW Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450 [TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109 [TBL] [Abstract][Full Text] [Related]
11. Liu W; Dai E; Liu Z; Ma C; Guo ZS; Bartlett DL Mol Ther Oncolytics; 2020 Jun; 17():350-360. PubMed ID: 32405533 [TBL] [Abstract][Full Text] [Related]
12. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418 [TBL] [Abstract][Full Text] [Related]
13. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic vaccinia virus armed with 4-1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1/PD-L1 blockade in a pancreatic cancer model. Ju Y; Dai F; Wang Y; Ye Z; Li Y; Ju S; Ge Y; Chen W Transl Oncol; 2024 Dec; 50():102151. PubMed ID: 39388958 [TBL] [Abstract][Full Text] [Related]
16. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy. Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916 [TBL] [Abstract][Full Text] [Related]
17. CXCL11 Signaling in the Tumor Microenvironment. Gao Q; Zhang Y Adv Exp Med Biol; 2021; 1302():41-50. PubMed ID: 34286440 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11. Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465 [TBL] [Abstract][Full Text] [Related]
19. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Chard LS; Maniati E; Wang P; Zhang Z; Gao D; Wang J; Cao F; Ahmed J; El Khouri M; Hughes J; Wang S; Li X; Denes B; Fodor I; Hagemann T; Lemoine NR; Wang Y Clin Cancer Res; 2015 Jan; 21(2):405-16. PubMed ID: 25416195 [TBL] [Abstract][Full Text] [Related]
20. Cancer-cell-secreted CXCL11 promoted CD8 Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]